Intervention

Gedatolisib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 10 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials10

Recruiting1

Common conditions16

Lead sponsors shown7

Clinical trials

10 shown

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899 · 2024-01-01

RECRUITING

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · 2022-12-08

ACTIVE_NOT_RECRUITING

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersNCT03911973 · 2019-04-17

ACTIVE_NOT_RECRUITING

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")NCT03400254 · 2019-02-26

WITHDRAWN

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast CancerNCT03243331 · 2018-01-19

COMPLETED

Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)NCT02920450 · 2017-09-25

TERMINATED

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsNCT03065062 · 2017-02-28

SUSPENDED

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerNCT02684032 · 2016-06-14

COMPLETED

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerNCT02626507 · 2016-01-01

UNKNOWN

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009NCT05134922

AVAILABLE

Common conditions

Breast Cancer4 Breast Neoplasm Malignant Female1 Genital Diseases, Male1 Head & Neck Cancer1 Lung Cancer Squamous Cell1 mCRPC (Metastatic Castration-resistant Prostate Cancer)1 Metastatic Breast Cancer1 Non-Small Cell Lung Cancer1 Pancreatic Cancer1 Prostate Cancer1 Prostatic Disease1 Prostatic Neoplasms, Castration-Resistant1 Solid Tumors1 TNBC - Triple-Negative Breast Cancer1 Triple Negative Breast Cancer1 Urogenital Diseases, Male1

Leading sponsors

Celcuity Inc 4 Abramson Cancer Center at Penn Medicine 1 Dana-Farber Cancer Institute 1 Hoffman Oncology 1 Kari Wisinski 1 Kathy Miller 1 University of Florida 1

Trial status mix

ACTIVE_NOT_RECRUITING2

COMPLETED2

AVAILABLE1

RECRUITING1

SUSPENDED1

TERMINATED1

UNKNOWN1

WITHDRAWN1

Phase mix

PHASE18

PHASE24

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.